ProCE Banner Activity

New Developments in Gene Therapy for Muscular Dystrophy

Audio

Expert faculty discuss gene therapy approaches in the management of muscular dystrophies.

Released: March 10, 2020

Expiration: March 09, 2021

No longer available for credit.

Share

Faculty

Richard S. Finkel

Richard S. Finkel, MD

Professor of Neurology
University of Central Florida College of Medicine
Division Chief, Pediatric Neurology
Nemours Childrens Hospital
Orlando, Florida

Kathryn R. Wagner

Kathryn R. Wagner, MD

Professor of Neuroloy and Neuroscience
Center for Genetic Muscle Disorders
Kennedy Krieger Institute
Johns Hopkins School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Sarepta Therapeutics

Faculty Disclosure

Primary Author

Richard S. Finkel, MD

Professor of Neurology
University of Central Florida College of Medicine
Division Chief, Pediatric Neurology
Nemours Childrens Hospital
Orlando, Florida

Richard S. Finkel, MD, has disclosed that he has received consulting fees from AveXis, Biogen, Catabasis, Ionis, Mitobridge, Neurogene, Novartis, ReveraGen, Roche, and Summit and funds for research support from AveXis, Bristol-Myers Squibb, Biogen, Catabasis, Capricor, Cytokinetics, Ionis, Lilly, MDA, ReveraGen, Scholar Rock, and Summit.

Kathryn R. Wagner, MD

Professor of Neuroloy and Neuroscience
Center for Genetic Muscle Disorders
Kennedy Krieger Institute
Johns Hopkins School of Medicine
Baltimore, Maryland

Kathryn R. Wagner, MD, PhD, has disclosed that she has received consulting fees from Arrowhead, AskBio, Dynacure, PTC, Santhera, Sarepta, and Wave.